Details of the Drug Combination

General Information of Drug Combination (ID: DC6ENQ2)

Drug Combination Name
Rivoceranib Rivoceranib
Indication
Disease Entry Status REF
Lung Adenocarcinoma Phase 1 [1]
Component Drugs Rivoceranib   DM13V0P Rivoceranib   DM13V0P
Small molecular drug Small molecular drug

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Rivoceranib
Disease Entry ICD 11 Status REF
Gastric adenocarcinoma 2B72 Phase 3 [2]
Sarcoma 2A60-2C35 Phase 2 [3]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Rivoceranib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Vascular endothelial growth factor receptor 2 (KDR) TTUTJGQ VGFR2_HUMAN Antagonist [2]
------------------------------------------------------------------------------------
Indication(s) of Rivoceranib
Disease Entry ICD 11 Status REF
Gastric adenocarcinoma 2B72 Phase 3 [2]
Sarcoma 2A60-2C35 Phase 2 [3]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Rivoceranib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Vascular endothelial growth factor receptor 2 (KDR) TTUTJGQ VGFR2_HUMAN Antagonist [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02691871) Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT04072042) BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced Sarcoma (BIOVAS). U.S. National Institutes of Health.